GlassScriptPhysician profile
Martin John Drost
NPI 1235135351
$5,910.58
in general payments reported to CMS, 2019-2025
39 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $146 · 2021: $768 · 2022: $700 · 2023: $1,059 · 2024: $1,370 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $805.22 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $687.76 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $495.53 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $430.74 | 2021-2025 | |
| Lilly USA, LLC | $424.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $285.79 | 2024 | Voquezna |
| Abbvie INC. | $272.29 | 2021-2025 | Linzess, Viberzi, Creon |
| Janssen Pharmaceuticals, INC | $231.56 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $224.98 | 2019-2025 | Eohilia |
| Idorsia Pharmaceuticals US INC | $219.41 | 2023-2024 | Quviviq |
| Amgen INC. | $185.39 | 2019-2025 | Otezla, Repatha, Otezla |
| Viiv Healthcare Company | $182.48 | 2024-2025 | Apretude |
| Astellas Pharma US INC | $151.88 | 2019-2020 | |
| Exact Sciences Corporation | $148.69 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $122.69 | 2023-2025 | Arexvy, Shingrix |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Drost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.